Wednesday, September 13, 2017 10:56:12 PM
By Chris Sandburg
Posted on September 13, 2017
Heat Biologics Inc (NASDAQ:HTBX) hasn’t had a great 2017. The company is down a little over 30% year-to-date and sentiment surrounding its lead development program has taken something of a hit on what amounts to nothing more than a lack of perceived operational advance.
Over the last few weeks, however, things look as though he might be starting to turn around. Back during mid-August, Heat went for as low as $0.47 per share. By September 12, this had topped out at $0.71 a share, a 50% appreciation, and the company now trades for just shy of $0.60 apiece.
So what’s causing the turnaround?
This is a biotechnology company with one of the most promising and exciting programs at this end of the space right now in play. The potential of this program, however, is being largely ignored on the back of (or at least, overshadowed by) expectations for a reverse split near term. Management has already picked up approval for the split and, if it comes into effect, it could bring with it some near-term short side activity.
With that said, however, the split is only necessary to get the company back above the $1 minimum bid threshold as required by NASDAQ. If Heat can push through this threshold organically, i.e. if the company can raise its own share price through – presumably – operational advance, the reverse split will be unnecessary.
So why is this important? Well, it means that the impact of any catalyst that gets the company running is sort of compounded by the increased proximity to the $1 mark. To put another way, if the company reports some positive news and the stock starts to run to the upside, markets see this run and associated with a reduced risk of a reverse split, because open market price is nearing the minimum bid threshold.
And that’s what we have seen recently.
The company’s lead development program is rooted in combining its own proprietary asset, a drug called HS-110, with Bristol-Myers Squibb Co (NYSE:BMY)’s Opdivo, in a non-small cell lung cancer (NSCLC) indication. There is a phase 2 trial ongoing right now and data to date has proven incredibly promising. If the outcome of the trial points towards efficacy, Heat will move into a phase 3 pivotal investigation that could serve to underpin a registration application in this indication.
On September 12, management announced that it had secured a type C meeting with the FDA to discuss the registrational pathway for the drug in question, as used in combination with the above-mentioned Opdivo.
This sort of meeting gives a company the opportunity to get some real insight into what the FDA is going to require from a new drug application (NDA) and, in turn, the outcome of the meeting can be a real catalyst for a company this end of the space. Especially, that is, if the outcome points towards a pathway that the drug in question has either already successfully traversed (say, for example, as part of a smaller scale trial) or if it points towards a similar pathway that markets feel shouldn’t bring with it any significant hurdles.
Going forward, then, that’s what we are looking for from Heat as a next major catalyst – the outcome of the type C meeting. Normally these meetings take place within 75 days of application, and we can assume that the company applied for the meeting at some point within the last month or so. This means we should see the meeting take place during the early fourth quarter at the outside.
And remember to keep in mind that the closer this one gets to one dollar, the quicker it’s going to accelerate towards that threshold.
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent NHWK News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/07/2024 04:15:18 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/03/2024 08:00:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/03/2024 11:18:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2024 12:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2024 12:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2024 12:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2024 09:00:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:52:07 PM
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 03/13/2024 10:17:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 10:01:13 AM
- Scorpius Holdings, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 03/12/2024 09:00:59 PM
- Scorpius Holdings, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 03/08/2024 05:20:00 AM
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/07/2024 09:18:08 PM
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:34:04 PM
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:00:09 PM
- NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:30:14 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:09 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM